5856 studies found for:    "breast cancer"
Show Display Options
Rank Status Study
21 Terminated
Has Results
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Conditions: Breast Neoplasms;   Breast Cancer;   Cancer of the Breast
Intervention: Drug: Lapatinib and Everolimus
22 Active, not recruiting Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
Conditions: Breast Neoplasms;   Breast Cancer;   Breast Tumors;   Cancer of Breast;   Cancer of the Breast;   Human Mammary Carcinoma;   Neoplasms, Breast
Interventions: Procedure: Remove tumor only;   Procedure: Removal of tumor and tissue
23 Recruiting BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: PI3K inhibitor BYL719;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: pharmacological studies
24 Active, not recruiting Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasms;   Breast Tumors;   Cancer;   Locally Recurrent and Metastatic Breast Cancer;   Metastases;   Metastatic Cancer;   Oncology;   Solid Tumors;   Tumors
Interventions: Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab;   Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib;   Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab;   Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
25 Active, not recruiting Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors
Conditions: Ductal Breast Carcinoma in Situ;   Breast Cancer, Stage I;   Breast Cancer, Stage II;   Breast Cancer, Stage III
Interventions: Dietary Supplement: omega-3 fatty acid;   Other: placebo;   Behavioral: Questionnaire administration
26 Recruiting Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Conditions: Metastatic Breast Cancer;   Breast Carcinoma;   HER-2 Positive Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Trastuzumab
27 Not yet recruiting Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Conditions: Breast Cancer;   Breast Carcinoma;   Breast Tumors;   Malignant Neoplasm of Breast
Interventions: Drug: Paclitaxel;   Drug: Alisertib
28 Recruiting Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Conditions: Breast Neoplasms;   Breast Cancer;   Breast Tumors;   Cancer of the Breast;   Neoplasms, Breast;   Tumors, Breast
Interventions: Drug: Eribulin;   Drug: Doxorubicin;   Drug: Cyclophosphamide
29 Active, not recruiting Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: eribulin mesylate;   Drug: carboplatin;   Procedure: biopsy
30 Unknown  Preoperative Herceptin and Navelbine for Breast Cancer
Conditions: Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Drug: Herceptin;   Drug: Navelbine;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Paclitaxel
31 Completed Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer
Conditions: Breast Cancer Stage IV;   Breast Cancer Stage I;   Breast Cancer Stage II
Intervention: Procedure: Blood Draw
32 Recruiting Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Conditions: Inflammatory Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
33 Unknown  Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives
Conditions: Breast Cancer;   Breast Cancer in Young Women;   Breast Cancer in Women With a Strong Family History
Interventions: Behavioral: Targeted;   Behavioral: Enhanced Tailored
34 Completed Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
Conditions: Advanced Breast Cancer;   Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: larotaxel (XRP9881);   Drug: trastuzumab
35 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: questionnaire administration
36 Terminated
Has Results
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
Conditions: Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: panitumumab;   Drug: paclitaxel;   Drug: carboplatin;   Procedure: laboratory biomarker analysis;   Procedure: immunohistochemistry staining method
37 Active, not recruiting Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Skin Metastases;   Stage IV Breast Cancer
Interventions: Drug: imiquimod;   Drug: Abraxane;   Other: laboratory biomarker analysis;   Genetic: RNA analysis;   Other: immunoenzyme technique
38 Active, not recruiting Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: tivantinib;   Other: laboratory biomarker analysis
39 Active, not recruiting Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
Conditions: Inflammatory Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Tubular Ductal Breast Carcinoma
Intervention: Radiation: External beam radiation therapy
40 Withdrawn Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery
Conditions: Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: azacitidine;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Genetic: nucleic acid sequencing;   Procedure: therapeutic conventional surgery

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years